Baxter International's (BAX) shares have bumped up against resistance at $60 over the past three months, but I'm reiterating my buy rating for the company's shares, first recommended on March 13, 2009, at a price of $51.16. Here's why:
Versatility remains Baxter's key. Baxter makes a variety of medical products across three divisions, including drugs and vaccines, dialysis equipment, and IV supplies. The company should record a FY2010 revenue increase of 7% to 10%, led by demand for recombinants, plasma proteins, and antibody therapies in its bioscience unit.
What Happened When Alex Kenjeev Paid His Student Loan in Cash
How to Save Money at the Movie Theater

